The Clinical Utility of a Novel Blood-Based Multi-Transcriptome Assay for the Diagnosis of Neuroendocrine Tumors of the Gastrointestinal Tract

Modlin, 2008, Priorities for improving the management of gastroenteropancreatic neuroendocrine tumors., J Natl Cancer Inst, 100, 1282, 10.1093/jnci/djn275

Palmer, 2008, Systematic evaluation of candidate blood markers for detecting ovarian cancer., PLoS One, 3, e2633, 10.1371/journal.pone.0002633

Modlin, 2014, Neuroendocrine tumor biomarkers: current status and perspectives., Neuroendocrinology, 100, 265, 10.1159/000368363

McDermott, 2011, Genomics and the continuum of cancer care., N Engl J Med, 364, 340, 10.1056/NEJMra0907178

Giandomenico, 2013, Improving the diagnosis and management of neuroendocrine tumors: utilizing new advances in biomarker and molecular imaging science., Neuroendocrinology, 28, 28

Modlin, 2006, Gastrointestinal carcinoids: the evolution of diagnostic strategies., J Clin Gastroenterol, 40, 572, 10.1097/00004836-200608000-00003

Turner, 2006, Circulating markers of prognosis and response to treatment in patients with midgut carcinoid tumours., Gut, 55, 1586, 10.1136/gut.2006.092320

Ardill, 2003, The importance of the measurement of circulating markers in patients with neuroendocrine tumours of the pancreas and gut., Endocr Relat Cancer, 10, 459, 10.1677/erc.0.0100459

Meijer, 2000, Discriminating capacity of indole markers in the diagnosis of carcinoid tumors., Clin Chem, 46, 1588, 10.1093/clinchem/46.10.1588

Metz, 2008, Gastrointestinal neuroendocrine tumors: pancreatic endocrine tumors., Gastroenterology, 135, 1469, 10.1053/j.gastro.2008.05.047

Bajetta, 1999, Chromogranin A, neuron specific enolase, carcinoembryonic antigen, and hydroxyindole acetic acid evaluation in patients with neuroendocrine tumors., Cancer, 86, 858, 10.1002/(SICI)1097-0142(19990901)86:5<858::AID-CNCR23>3.0.CO;2-8

Khan, 2011, Circulating tumor cells and EpCAM expression in neuroendocrine tumors., Clin Cancer Res, 17, 337, 10.1158/1078-0432.CCR-10-1776

Modlin, 2008, The current status of gastroenteropancreatic neuroendocrine tumors., Lancet Oncol, 9, 61, 10.1016/S1470-2045(07)70410-2

Kanakis, 2012, Biochemical markers for gastroenteropancreatic neuroendocrine tumours (GEP-NETs)., Best Pract Res Clin Gastroenterol, 26, 791, 10.1016/j.bpg.2012.12.006

Stridsberg, 1995, Measurement of chromogranin A, chromogranin B (secretogranin I), chromogranin C (secretogranin II) and pancreastatin in plasma and urine from patients with carcinoid tumours and endocrine pancreatic tumours., J Endocrinol, 144, 49, 10.1677/joe.0.1440049

Portela-Gomes, 2001, Selective processing of chromogranin A in the different islet cells in human pancreas., J Histochem Cytochem, 49, 483, 10.1177/002215540104900408

Lawrence, 2011, The clinical relevance of chromogranin A as a biomarker for gastroenteropancreatic neuroendocrine tumors., Endocrinol Metab Clin North Am, 40, 111, 10.1016/j.ecl.2010.12.001

Modlin, 2010, Chromogranin Abiological function and clinical utility in neuro endocrine tumor disease., Ann Surg Oncol, 17, 2427, 10.1245/s10434-010-1006-3

Marotta, 2012, Limitations of chromogranin A in clinical practice., Biomarkers, 17, 186, 10.3109/1354750X.2012.654511

Wu, 2000, Elevated serum chromogranin A is detectable in patients with carcinomas at advanced disease stages., Ann Clin Lab Sci, 30, 175

Sciarra, 2005, Chromogranin A expression in familial versus sporadic prostate cancer., Urology, 66, 1010, 10.1016/j.urology.2005.05.045

Hsiao, 1990, Chromogranin A in uremia: progressive retention of immunoreactive fragments., Kidney Int, 37, 955, 10.1038/ki.1990.71

Hanahan, 2011, Hallmarks of cancer: the next generation., Cell, 144, 646, 10.1016/j.cell.2011.02.013

Reichard, 2013, Hematological diseases: prototypical conditions requiring the diagnostic and prognostic use of molecular data., Semin Diagn Pathol, 30, 382, 10.1053/j.semdp.2013.11.006

Modlin, 2014, Gut neuroendocrine tumor blood qPCR fingerprint assay: characteristics and reproducibility., Clin Chem, 52, 419

Halperin, 2014, A tale of two tumors: treating pancreatic and extrapancreatic neuroendocrine tumors., Annu Rev Med, 17, 17

Lewis, 2013, Molecular pathology and genetics of gastrointestinal neuroendocrine tumours., Curr Opin Endocrinol Diabetes Obes, 4, 4

Raza, 2012, Analytical variables influencing the HCV RNA determination by TaqMan real-time PCR in routine clinical laboratory practice., Mol Biol Rep, 39, 7421, 10.1007/s11033-012-1574-3

Modlin, 2009, Principal component analysis, hierarchical clustering, and decision tree assessment of plasma mRNA and hormone levels as an early detection strategy for small intestinal neuroendocrine (carcinoid) tumors., Ann Surg Oncol, 16, 487, 10.1245/s10434-008-0251-1

Fleige, 2006, Comparison of relative mRNA quantification models and the impact of RNA integrity in quantitative real-time RT-PCR., Biotechnol Lett, 28, 1601, 10.1007/s10529-006-9127-2

Modlin, 2013, A multitranscript blood neuroendocrine tumor molecular signature to identify treatment efficacy and disease progress., J Clin Oncol, 31, A4137, 10.1200/jco.2013.31.15_suppl.4137

Hanley, 1982, The meaning and use of the area under a receiver operating characteristic (ROC) curve., Radiology, 143, 29, 10.1148/radiology.143.1.7063747

Hanley, 1983, A method of comparing the areas under receiver operating characteristic curves derived from the same cases., Radiology, 148, 839, 10.1148/radiology.148.3.6878708

Modlin, 2014, A multianalyte PCR blood test outperforms single analyte ELISAs for neuroendocrine tumor detection., Endocr Relat Cancer, 21, 615, 10.1530/ERC-14-0190

Modlin, 2014, A PCR blood test outperforms chromogranin A in carcinoid detection and is unaffected by PPIs., Endocr Connect, 14, 14

Syversen, 1995, Neuroendocrine differentiation in colorectal carcinomas., Eur J Gastroenterol Hepatol, 7, 667

Syversen, 2004, Clinical significance of elevated serum chromogranin A levels., Scand J Gastroenterol, 39, 969, 10.1080/00365520410003362

Fisher, 2015, Molecular foundations for personalized therapy in prostate cancer., Curr Drug Targets, 16, 103, 10.2174/1389450115666141229154500

Wang, 2014, Invasive neuroendocrine carcinoma of the breast: a population-based study from the surveillance, epidemiology and end results (SEER) database., BMC Cancer, 14, 147, 10.1186/1471-2407-14-147

Raghav, 2013, Small bowel adenocarcinomasexisting evidence and evolving paradigms., Nat Rev Clin Oncol, 10, 534, 10.1038/nrclinonc.2013.132

Manfredi, 2013, Non-hyperfunctioning neuroendocrine tumours of the pancreas: MR imaging appearance and correlation with their biological behaviour., Eur Radiol, 23, 3029, 10.1007/s00330-013-2929-4

Kloppel, 2014, Intraductal neoplasms of the pancreas., Semin Diagn Pathol, 31, 452, 10.1053/j.semdp.2014.08.005

Gill, 2009, Pancreatic neuroendocrine tumors among patients with intraductal papillary mucinous neoplasms: real association or just a coincidence?, JOP, 10, 515

Goh, 2006, Clinicopathological features of patients with concomitant intraductal papillary mucinous neoplasm of the pancreas and pancreatic endocrine neoplasm., Pancreatology, 6, 520, 10.1159/000097361

Marrache, 2005, Endocrine tumor and intraductal papillary mucinous neoplasm of the pancreas: a fortuitous association?, Pancreas, 31, 79, 10.1097/01.mpa.0000164453.46394.07

Ishida, 2013, Concomitant intraductal papillary mucinous neoplasm and neuroendocrine tumor of the pancreas., Oncol Lett, 5, 63, 10.3892/ol.2012.952

Larghi, 2009, Concomitant intraductal papillary mucinous neoplasm and pancreatic endocrine tumour: report of two cases and review of the literature., Dig Liver Dis, 41, 759, 10.1016/j.dld.2009.01.005

Stridsberg, 2003, A comparison between three commercial kits for chromogranin A measurements., J Endocrinol, 177, 337, 10.1677/joe.0.1770337

Faltin, 2013, Current methods for fluorescence-based universal sequence-dependent detection of nucleic acids in homogenous assays and clinical applications., Clin Chem, 59, 1567, 10.1373/clinchem.2013.205211

Eastman, 2012, Characterization of a multiplex, 12-biomarker test for rheumatoid arthritis., J Pharm Biomed Anal, 70, 415, 10.1016/j.jpba.2012.06.003

Cornejo, 2014, Theranostic and molecular classification of breast cancer., Arch Pathol Lab Med, 138, 44, 10.5858/arpa.2012-0442-RA